Sanofi CFO on Share Buyback, R&D, Trump Administration

The transcript discusses a company's financial strategies, including a $5 billion share buyback and dividend increase, aimed at mitigating dilution from a business separation. It highlights significant R&D investments leading to strong sales growth, though not directly linked to recent R&D spending. The company faces pressure to manufacture more in the US due to policy changes, despite its strong European industrial base. Success in the vaccine sector, particularly with RSV vaccines, is noted, with plans for continued investment in this area.

What is the significance of the investment in R&D as mentioned in the text?

What was the financial outcome of the RSV vaccine for young children in its first year of marketing?